Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$16,500.00   |  '

Primary Sclerosing Cholangitis | Executive Insights | US |2019

Login to access report north_east
Buy report north_east

MARKET OUTLOOK

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colon cancer. The median age of diagnosis is 42 years, and it is more common in men than in women. Despite the severity of PSC, no therapies are approved to treat it. Current treatment with UDCA and fenofibrates offers some clinical benefit but does not prevent the progression to liver cirrhosis or cholangiocarcinoma. However, several therapies with novel mechanisms of action are in development to treat PSC and will be used first line if they prove safe and efficacious. These therapies will capitalize on the immense unmet need in this space.

QUESTIONS ANSWERED

  •  What are the key areas of unmet need and opportunity in the PSC therapy market?
  •  What is the prevalence of PSC in the United States?
  • How are PSC patients currently treated in the United States?
  •  What therapies are in development for PSC?
  •  How does each current and future player influence the market, and how will this scenario change in the future?
  •  What are the key drivers and limiters of the PSC therapy market?

CONTENT HIGHLIGHTS

  • Geography: United States
  • Primary Research: Three KOL interviews in December 2019
  • Key Companies Covered:  Cymabay, Gilead, Intercept Pharmaceuticals, Dr. Falk Pharma, High Tide Biopharma, Acorda Therapeutics, Immunic
  • Drugs Covered:  Seladelpar, cilofexor, norursodeoxycholic acid, Ocaliva, HTD 1801, timolumab, vidofludimus calcium

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
north_east
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east